We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.04 | -3.02% | 33.35 | 33.50 | 32.825 | 33.24 | 13,380,030 | 01:00:00 |
From Nov 2021 to Nov 2024
By Anthony O. Goriainoff
GSK PLC said Monday that the U.S. Food and Drug Administration has approved Boostrix for immunization during the third trimester of pregnancy to help prevent pertussis, or whooping cough, in infants under two months old.
The U.K.-based maker of cancer and asthma medications said the vaccine--which is given during pregnancy--passes antibodies to babies before birth. The vaccine is also indicated against tetanus, diphtheria and pertussis in individuals aged 10 years and older, GSK said.
Boostrix is currently approved in more than 80 countries including most EU countries, as well as Canada, Australia and New Zealand, as a vaccine for tetanus, diphtheria and pertussis, the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
October 10, 2022 02:33 ET (06:33 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
